E Pelz

TL;DR: Clinical findings are pain, mass, hyperemia, and inflammation, and the management of GM is controversial; most authors use a therapy regimen starting with antibiotics and corticosteroids, followed by continuous steroid therapy and surgery in patients with persisting symptoms.

TL;DR: Combination of proliferation/immune markers and PAM50 subtype could allow patient selection for further deescalated chemotherapy and/or immune treatment approaches, and predictive markers for deescalation taxane/carbo use in TNBC need to be identified.

TL;DR: Prosigna testing was associated with increased patient and physician confidence in treatment decisions, and with decreased patient anxiety and improved well-being.

TL;DR: The recently described variant of ILBC with solid‐papillary‐like growth pattern is confirmed and evidence that it evolves from classical ILBC by subclonal evolution is provided.

TL;DR: This data indicates that continuation of prophylactic mastectomy after second line treatment with chemotherapy or neoadjuvant regimens is a viable treatment option for HER2+ early breast cancer in women with EBC.